Lisdexamfetamine Dimesylate Chewable Tablet Shortage: Current Availability and Manufacturer Updates

Source: FDA · United States

According to the U.S. Census Bureau's American Community Survey (ACS) 5-year estimates, the CDC PLACES population-level health analysis, and the CMS Hospital Compare quality data, Areazine publishes editorial articles drawing on more than 19,000 U.S. city profiles. See our methodology for full source attribution and refresh cadence.

The FDA reports a current shortage of Lisdexamfetamine Dimesylate chewable tablets, with some manufacturers noting limited supplies across multiple dosage strengths.

What this FDA drug-shortage notice tells you, and what most readers miss

This notice was issued by FDA on February 11, 2026 and geographically references United States. Its severity classification of "low" signals how the issuing agency weighs the risk of harm if no action is taken — "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to — Drug Shortages — determines the regulatory framework behind it, which shapes what remedies (refunds, replacements, recalls, evacuations) are available to affected individuals and who holds statutory responsibility for enforcement.

Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to read it as a data point about the issuing system: how quickly FDA detected the hazard, how precise the geographic or product-identifier scope is, and whether similar notices have clustered in the same category or region in the last 90 days. Cluster patterns frequently precede a broader regulatory action — a single localized FDA drug-shortage notice is isolated; three of them within a quarter often indicate a supply-chain, infrastructure, or seasonal driver that will keep producing notices until something structural changes.

For decision-making, Areazine pairs each alert with the original agency URL, the full agency name, and a timestamp so you can verify the notice against the primary source before acting on it. Tags on this item (drug-shortage, fda, medication, Lisdexamfetamine-Dimesylate) map to related alerts in the same area of risk — browsing them together gives a clearer picture than any single notice alone, because the shape of an ongoing issue only becomes visible across multiple sequential alerts.

Lisdexamfetamine Dimesylate Chewable Tablet Shortage: Current Availability and Manufacturer Updates

What's in Shortage

The FDA has identified a current shortage of Lisdexamfetamine Dimesylate in chewable tablet form. This medication, which falls under the therapeutic category of Psychiatry, is used by patients for various psychiatric conditions. The shortage was initially posted on July 14, 2023, and the status was most recently updated on February 3, 2026.

Which Manufacturers Are Affected

Currently, two manufacturers are supplying the market, though availability may vary by location and dosage strength.

  • Novadoz Pharmaceuticals LLC

    • Status: Available (Note: Limited supply from Manufacturers)
    • Presentations: 10 mg (NDC 72205-132-91), 20 mg (NDC 72205-133-91), 30 mg (NDC 72205-134-91), 40 mg (NDC 72205-135-91), 50 mg (NDC 72205-136-91), and 60 mg (NDC 72205-137-91).
    • Contact Info: (855) 668-2369; customerservice@novadozpharma.com
  • Sun Pharmaceutical Industries, Inc.

    • Status: Available
    • Presentations: 10 mg (NDC 57664-083-88), 20 mg (NDC 57664-084-88), 30 mg (NDC 57664-085-88), 40 mg (NDC 57664-086-88), 50 mg (NDC 57664-087-88), and 60 mg (NDC 57664-088-88).
    • Contact Info: 800-818-4555

Why There's a Shortage

The FDA source data does not provide a specific reason for the current supply limitations or the limited supply reported by manufacturers.

What Patients Should Do

If you are prescribed Lisdexamfetamine Dimesylate chewable tablets and are having difficulty filling your prescription, consider the following steps:

  • Speak with your pharmacist: They can provide information on current stock levels or check if the medication is available at other nearby locations.
  • Consult your healthcare provider: Discuss your treatment options and ask about potential alternatives if your specific dosage is unavailable.
  • Contact the manufacturers: You may use the contact information listed above to inquire about the availability of specific lots or presentations.

Disclaimer: Patients should always consult with their healthcare provider or pharmacist regarding medical concerns or changes to their medication regimen.

Source

Attribution: FDA Drug Shortage Database

Original source: FDA Official Notice ↗

All Drug Shortages →

Frequently Asked Questions

Common questions about this FDA drug-shortage notice.

What is this FDA drug-shortage notice about?
The FDA reports a current shortage of Lisdexamfetamine Dimesylate chewable tablets, with some manufacturers noting limited supplies across multiple dosage strengths.
Which agency issued this alert?
This alert was issued by FDA. The original notice is available at the source link at the bottom of this article.
How severe is this alert?
This alert is classified as "low" severity. No immediate action required, but stay aware.
What area is affected?
This alert affects United States. Check with FDA for the most current geographic scope.
Where can I find more Drug Shortages updates?
Browse the full Drug Shortages feed on Areazine at areazine.com/drug-shortages/ for the latest updates from FDA and other agencies.